Formulary Search

You are here : Home > Formulary Search

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Return to the search options.

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A-Z of Drugs

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search Results : Menopausal disorders (Gabapentin - Menopausal disorders)

Records returned : 37 (on 16 Jul 2025 at 22:52:06). Return to search results for ' Menopausal disorders '.

Show Icon and Status Keys Hide Icon and Status Keys

Icon Key

NFD1

Non formulary

NFD2

Not assessed for formulary status. Apply to APC / DTC before use.

Controlled drug. Prescribing and/or storage requirements may apply

Restrictions apply

Safety Alert

Unlicensed - no UK marketing license in place

Off Label

Not licensed for this indication.

NHSE

Treatment commissioned by NHS England

CDF

Cancer Drugs Fund

ICB

Treatment commissioned by the ICB

BlueTeq form to be completed

NICE

Link to the NICE website

Low carbon device

SPC

View the treatment summary for {padindicationname} on https://www.medicines.org.uk

Status Key

Red

Specialist ONLY drugs - treatment initiated and continued by specialist clinicians

Amber

Prescribing initiated and stabilised by specialist but has potential to transfer to primary care under a formal shared care agreement

Green

GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing.

Green (see narrative)

GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing. Please refer to the narrative on the Drug Profile page where additional information may be conveyed as to the place in therapy or restrictions for use that have been locally agreed.

Non Formulary

Not recommended for use in any health setting across the Surrey Heartlands Integrated Care System

Blue

Prescribing initiated and stabilised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.

See narrative

See narrative - may be applied in instances where a traffic light status has not yet been agreed but an entry to the formulary has been made to clarify interim arrangements.

Drug

Indication

Status

Restrictions/Comments

Formulary Status

Links

1. Gabapentin

Drug:

Gabapentin

Indication :

Menopausal disorders

Status :

Green (see narrative)

Formulations :

Capsules

Restrictions / Comments:

Important

Off-label use.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

Off Label

SPC

2. Clonidine hydrochloride

Drug:

Clonidine hydrochloride

Indication :

Menopausal disorders

Status :

Green

Formulations :

Tablets

Restrictions / Comments:

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

SPC

3. Estradiol

Drug:

Estradiol

Indication :

Menopausal disorders

Status :

Green

Formulations :

Tablets

Restrictions / Comments:

Important

Preferred

Elleste Solo tablets - 1st line

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

SPC

4. Estradiol

Drug:

Estradiol

Indication :

Menopausal disorders

Status :

Green

Formulations :

Patches

Restrictions / Comments:

Important

Estradiol patches 2nd line to tablets. No preferred patch recommendation has been made due to current stock shortages (Estraderm, Estradot, Evorel, FemSeven, Progynova TS)

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

SPC

5. Estradiol

Drug:

Estradiol

Indication :

Menopausal disorders

Status :

Green

Formulations :

Spray

Restrictions / Comments:

Important

Lenzetto spray. Caution with higher than licensed doses. Max supply of 20 containers per year to stay within licensed dose.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

SPC

10. Estradiol

Drug:

Estradiol

Indication :

Menopausal disorders

Status :

Green (see narrative)

Formulations :

Restrictions / Comments:

Important

Oestrogel is the preferred gel option. Sandrena is an alternative option.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

SPC

11. Estradiol

Drug:

Estradiol

Indication :

Menopausal disorders

Status :

Green (see narrative)

Formulations :

Tablets

Restrictions / Comments:

Important

Progynova and Zumenon tablets NOT 1st line. Only prescribe where Elleste Solo tablets are unavailable.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

SPC

6. Estradiol with dydrogesterone

Drug:

Estradiol with dydrogesterone

Indication :

Menopausal disorders

Status :

Green

Formulations :

Tablets

Restrictions / Comments:

Important

Preferred

Femoston tablets - 1st line for women requiring sequential combined therapy.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

SPC

7. Estradiol with dydrogesterone

Drug:

Estradiol with dydrogesterone

Indication :

Menopausal disorders

Status :

Green

Formulations :

Tablets

Restrictions / Comments:

Important

Preferred

Femoston Conti - 1st line for women requiring continuous combined therapy.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

SPC

8. Estradiol with progesterone

Drug:

Estradiol with progesterone

Indication :

Menopausal disorders

Status :

Green

Formulations :

Capsules

Restrictions / Comments:

Important

Preferred

Bijuve capsules - 1st line for women requiring continuous combined therapy.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

SPC

9. Tibolone

Drug:

Tibolone

Indication :

Menopausal disorders

Status :

Green

Formulations :

Tablets

Restrictions / Comments:

Important

Prescribe generically

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

SPC

12. Estradiol with levonorgestrel

Drug:

Estradiol with levonorgestrel

Indication :

Menopausal disorders

Status :

Green (see narrative)

Formulations :

Patches

Restrictions / Comments:

Important

Femseven Conti patches - less preferred. Only use in the event of product shortages.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

SPC

13. Estradiol with norethisterone

Drug:

Estradiol with norethisterone

Indication :

Menopausal disorders

Status :

Green (see narrative)

Formulations :

Tablets

Restrictions / Comments:

Important

Elleste Duet Conti - 2nd line for women requiring continuous combined therapy but with poor cycle control on Femoston Conti (1st-line).

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

SPC

14. Estradiol with norethisterone

Drug:

Estradiol with norethisterone

Indication :

Menopausal disorders

Status :

Green (see narrative)

Formulations :

Patches

Restrictions / Comments:

Important

Evorel Conti patches - preferred in women with risk factors for VTE or migraine. Otherwise use a 1st-line oral option.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

SPC

15. Estradiol with norethisterone

Drug:

Estradiol with norethisterone

Indication :

Menopausal disorders

Status :

Green (see narrative)

Formulations :

Tablets

Restrictions / Comments:

Important

Kliofem tablets - 2nd line in women requiring continuous combined therapy but with poor cycle control on Femoston Conti (1st-line)

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

SPC

16. Estradiol with norethisterone

Drug:

Estradiol with norethisterone

Indication :

Menopausal disorders

Status :

Green (see narrative)

Formulations :

Tablets

Restrictions / Comments:

Important

Kliovance tablets - 2nd line in women requiring continuous combined therapy but with poor cycle control on Femoston Conti (1st-line)

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

SPC

17. Estradiol with norethisterone

Drug:

Estradiol with norethisterone

Indication :

Menopausal disorders

Status :

Green (see narrative)

Formulations :

Patches

Restrictions / Comments:

Important

Evorel Sequi patches 2nd-line. Preferred option in women with risk factors for VTE or migraine.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

SPC

18. Estradiol with norethisterone

Drug:

Estradiol with norethisterone

Indication :

Menopausal disorders

Status :

Green (see narrative)

Formulations :

Tablets

Restrictions / Comments:

Important

Elleste Duet tablets 2nd line. For women requiring sequential combined therapy but with poor cycle control on Femoston (1st-line).

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

SPC

19. Estradiol with norethisterone

Drug:

Estradiol with norethisterone

Indication :

Menopausal disorders

Status :

Green (see narrative)

Formulations :

Tablets

Restrictions / Comments:

Important

Novofem tablets - Only use if there are product shortages with Elleste Duet

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

SPC

32. Estradiol with norethisterone

Drug:

Estradiol with norethisterone

Indication :

Menopausal disorders

Status :

Non Formulary

Formulations :

Tablets

Restrictions / Comments:

Important

Trisequens tablets - consider changing to newer, 1st or 2nd line options.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

SPC

20. Levonorgestrel

Drug:

Levonorgestrel

Indication :

Menopausal disorders

Status :

Green (see narrative)

Formulations :

Intrauterine device (progestogen only)

Restrictions / Comments:

Important

Levonorgestrel recommended for replacement every 5 years (off-label use) as per BMS: https://thebms.org.uk/wp-content/uploads/2023/04/14-BMS-TfC-Progestogens-and-endometrial-protection-APR2023-A.pdf

Mirena - licensed for endometrial protection but only for a duration of 4 years. Agreed to use for a duration of 5 years before replacement (off-label).

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

Off Label

SPC

21. Medroxyprogesterone acetate

Drug:

Medroxyprogesterone acetate

Indication :

Menopausal disorders

Status :

Green (see narrative)

Formulations :

Tablets

Restrictions / Comments:

Important

10mg tablets for adjunctive progestogen therapy

2nd line for endometrial protection in women who have abnormal bleeding on other HRT.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

SPC

22. Paroxetine

Drug:

Paroxetine

Indication :

Menopausal disorders

Status :

Green (see narrative)

Formulations :

Tablets

Restrictions / Comments:

Important

Off-label use.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

Off Label

SPC

23. Pregabalin

Drug:

Pregabalin

Indication :

Menopausal disorders

Status :

Green (see narrative)

Formulations :

Capsules

Restrictions / Comments:

Important

Off-label use.

Off-label use

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

Off Label

SPC

24. Progesterone

Drug:

Progesterone

Indication :

Menopausal disorders

Status :

Green (see narrative)

Formulations :

Capsules

Restrictions / Comments:

Important

Preferred

Prescribe generically. Micronised progesterone oral capsules.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

SPC

35. Progesterone

Drug:

Progesterone

Indication :

Menopausal disorders

Status :

Non Formulary

Formulations :

Pessaries

Restrictions / Comments:

Important

Progesterone pessaries have not been agreed for use as endometrial protection.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

NFD1

SPC

25. Venlafaxine

Drug:

Venlafaxine

Indication :

Menopausal disorders

Status :

Green (see narrative)

Formulations :

Modified release tablets

Restrictions / Comments:

Important

Off-label use.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

Off Label

SPC

26. Conjugated oestrogens

Drug:

Conjugated oestrogens

Indication :

Menopausal disorders

Status :

Non Formulary

Formulations :

Tablets

Restrictions / Comments:

Important

Recommend switching to a newer, lower risk formulation.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

SPC

27. Conjugated oestrogens with medroxyprogesterone

Drug:

Conjugated oestrogens with medroxyprogesterone

Indication :

Menopausal disorders

Status :

Non Formulary

Formulations :

Modified release tablets

Restrictions / Comments:

Important

Premique Low Dose - no longer recommended. Switch to a newer, lower risk formulation.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

SPC

28. Drospirenone

Drug:

Drospirenone

Indication :

Menopausal disorders

Status :

Non Formulary

Formulations :

Tablets

Restrictions / Comments:

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

NFD1

Off Label

SPC

29. Duavive

Drug:

Duavive

Indication :

Menopausal disorders

Status :

Non Formulary

Formulations :

Not Specified

Restrictions / Comments:

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

SPC

30. Estradiol with medroxyprogesterone

Drug:

Estradiol with medroxyprogesterone

Indication :

Menopausal disorders

Status :

Non Formulary

Formulations :

Tablets

Restrictions / Comments:

Important

Tridestra tablets - consider changing to a newer, 1st or 2nd line option.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

SPC

31. Estradiol with medroxyprogesterone

Drug:

Estradiol with medroxyprogesterone

Indication :

Menopausal disorders

Status :

Non Formulary

Formulations :

Tablets

Restrictions / Comments:

Important

Indivina tablets - consider changing to a newer, 1st or 2nd line option.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

SPC

33. Ethinylestradiol

Drug:

Ethinylestradiol

Indication :

Menopausal disorders

Status :

Non Formulary

Formulations :

Not Specified

Restrictions / Comments:

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

SPC

34. Non-Hormonal lubricants

Drug:

Non-Hormonal lubricants

Indication :

Menopausal disorders

Status :

Non Formulary

Formulations :

Not Specified

Restrictions / Comments:

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

SPC

36. St Johns Wort

Drug:

St Johns Wort

Indication :

Menopausal disorders

Status :

Non Formulary

Formulations :

Not Specified

Restrictions / Comments:

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

NFD1

SPC

37. Fezolinetant

Drug:

Fezolinetant

Indication :

Menopausal disorders

Status :

See narrative

Restrictions / Comments:

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

NFD2

SPC